Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.
Shares of American pharmaceutical company Novavax (NVAX) fell 19% on reports that the U.S. Food and Drug Administration (FDA) ...
Standing desks may increase the risk of swollen veins and blood clots, a study in the International Journal of Epidemiology ...
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...
Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...
A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...
CIDRAP reports that federal health officials know of 90 cases of Oropouche virus from five states, mostly from Florida, although none of the cases is known to have been sexually transmitted. Plus: ...
On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...
Dow, S&P 500, and Nasdaq futures are rising in premarket trading Thursday as the stock market reacts to Taiwan Semiconductor earnings in light of the recent ASML selloff.
The number of people with a medical bill on a credit report is down. But researchers found the decline was smaller in places ...
Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...
Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback